Carbamazepine, Sodium Valproate and Levetiracetam Modulate Wnt Inhibitors in Indian Women with Epilepsy

Bushra Parveen; Manjari Tripathi; Divya Vohora

doi:10.1055/s-0040-1712841

Annals of the National Academy of Medical Sciences (India), Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2018; 54(03): 153-159
DOI: 10.1055/s-0040-1712841

Original Article

Carbamazepine, Sodium Valproate and Levetiracetam Modulate Wnt Inhibitors in Indian Women with Epilepsy

Bushra Parveen

School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi

,

Manjari Tripathi

Department of Neurology, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi

,

Divya Vohora

School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi

› Institutsangaben

Abstract

als PDF herunterladen

ABSTRACT

Background: Antiepileptic drug (AED) therapy has been claimed to deteriorate bone health. Majority of the research was inclined towards vitamin-D deficiency as the patho-mechanism. However, after the role of Wnt in bone metabolism was discovered, it has paved way for investigating the role of Wnt inhibitors in mediating effects on bone accrual. Recently, we have reported the modulation of two Wnt inhibitors, sclerostin and dickkopf-1 (DKK-1), following AED therapy in Indian women with epilepsy, however, the subgroup analysis for individual drug is elucidated in this report.

Methods: Individual analysis for our earlier cross-sectional study on three AEDs, carbamazepine (CBZ), sodium valproate (SVP) and levetiracetam (LTM), on sclerostin and dickkopf-1, and their correlation with receptor activator of nuclear factor kappaB ligand (RANKL) and serum 25-hydroxy vitamin D (25OHD) was assessed in Indian women with epilepsy.

Results: We observed enhanced sclerostin and 25OHD levels with all three AEDs while serum RANKL was higher with SVP and LTM only. Further, serum DKK-1 levels were lowered with CBZ and LTM. Sclerostin showed a positive correlation with RANKL in CBZ group, while DKK-1 presented no such relationship.

Conclusion: As sclerostin is more specific than DKK-1, we may conclude that these drugs may compromise bone health through disturbance in Wnt signaling mechanisms.

Keywords

sclerostin - DKK-1 - RANKL - 25OHD - sodium valproate - carbamazepine - levetiracetam

PDF (126 kb)

Referenzen

References
1 Krishnan V, Bryant HU, MacDougald OA (2006). Regulation of bone mass by Wnt signaling. J Clin Invest 116: 1202-1209.
2 Kim JH, Liu X, Wang J, et al (2013). Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis 5: 13-31.
3 Albaghdadi O, Alhalabi MS, Alourfi Z, Lama A (2016). Bone health and vitamin D status in young epilepsy patients on valproate monotherapy. Clin Neurol Neurosurg 146: 52-56.
4 Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA (2012). High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: The Center of Excellence for Osteoporosis Research Study. J Bone Miner Res 27: 2592-2602.
5 Uemura H, Yasui T, Miyatani Y, et al (2 008). C i r cula ting pr ofiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women. J Endocrinol Invest 3: 163-168.
6 Oh KW, Rhee EJ, Lee WY, et al (2005). Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol (Oxf) 62: 92-98.
7 Xu XJ, Shen L, Yang YP, et al (2013). Serum β-Catenin levels associated with the ratio of RANKL/OPG in patients with postmenopausal osteoporosis. Intl J Endocrinol 2013: 534352.
8 Parveen B, Tripathi M, Vohora D (2018). A cross-sectional study to assess the modulation of Wnt Inhibitors following anti-epileptic drug therapy and their correlation with vitamin D and receptor activator of nuclear factor κ B ligand in Indian women with epilepsy. Basic Clin Pharmacol Toxicol 123(3): 271-276.
9 Parveen B, Tiwari AK, Jain M, et al (2018). The anti-epileptic drugs valproate, carbamazepine and levetiracetam cause bone loss and modulate Wnt inhibitors in normal and ovariectomised rats. Bone 113: 57–67.
10 Gifre L, Ruiz-Gaspa S, Monegal A, et al (2013). Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and DKK-1) and their relationship with bone turnover. Bone 57: 272-276.
11 Li X, Grisanti M, Fan W, et al (2011). Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res 26: 2610-2621.
12 Ke HZ, Richards WG, Li X, Ominsky MS (2012). Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocrine Rev 33: 747-783.
13 Elwakkad AS, El Elshamy KA, H (2008). Fish liver oil and propolis as protective natural products against the effect of the anti-epileptic drug valproate on immunological markers of bone formation in rats. Epilepsy Res 80: 47-56.
14 Teitelbaum SL, Ross FP (2003). Genetic regulation of osteoclast development and function. Nat Rev Genet 4: 638-649.
15 Kim JH, Kim K, Youn BU, et al (2011). RANKL induces NFATc1 acetylation and stability via histone acetyl transferases during osteoclast differentiation. Biochem J 436: 253-262.
16 Stettner M, Krämer G, Strauss A, et al (2012). Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. Eur J Cancer Prev 21: 55-64.
17 Göttlicher M, Minucci S, Zhu P, et al (2001). Valproic acid defines a novel class of HDAC in hibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.